Alkem Laboratories Ltd
NSE: ALKEM BSE: 539523
₹5402.50
(-7.97%)
Fri, 13 Feb 2026, 09:00 pm
Market Cap700.45B
PE Ratio27.36
Dividend0.77
Company History
1973
- The Company was incorporated as a private limited company 'Alkem Laboratories Private Limited'.
1978
- The Company established its first plant at Taloja, Maharashtra.
1988
- The Company became a deemed public limited company.
1992
- The Company established its manufacturing facility in Mandwa, Maharashtra.
1998
- The Company established its Kachigam manufacturing facility in Gujarat.
2001
- Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company.
2002
- The Company established its Amaliya manufacturing facility in Gujarat.
- The Company was awarded the Pharma Business and Technology Excellence Award as 'India's Most Esteemed Pharmaceutical Company'.
2003
- The Company set up its research and development facility at Taloja, Maharashtra.
2004
- The product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand.
2005
- The Company established its manufacturing facility in Baddi, Himachal Pradesh.
- The Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards.
- The facility in Mandwa, Maharashtra was converted into an API facility.
2006
- The anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India.
2007
- The Company established its manufacturing facility in Kumrek, Sikkim.
- The Company filed its first ANDA in the United States for the drug Amlodipine.
- The Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra.
2009
- The Company acquired Pharmacor, a generic pharma company in Australia.
- The Company received a certificate of appreciation for outstanding export performance in the category of formulations.
- The Company received a certificate of appreciation in the category of 'Formulation Experts'.
2010
- The Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC.
2011
- The Company acquired Enzene Bio sciences Limited.
2012
- The Company acquired an API manufacturing facility in the United States.
2013
- The Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit.
2014
- The Company acquired Clindac.
- The product 'Clavam' was awarded as the 'Brand of the Year' at the AWACS Award, 2014.
2015
- The Company acquired a formulation manufacturing facility in the United States.
2016
- Alkem's Mandva Plant obtained the Establishment Inspection Report from the US FDA.
- Alkem received the EIR from the US FDA for its Daman formulation facility.
2017
- Alkem formed a marketing alliance with Haw Par to exclusively market, sell, and distribute the Tiger Balam range of products in India.
- Alkem started direct consumer marketing for Pregakem and Livoerb.
- Alkem received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg.
2018
- Alkem's revenue from the US market crossed USD 200 million in annual sales.
- The brand 'Clavam' received the 'Brand of the Year 2018' award at AWACS AWARDS FOR Marketing Excellence.
2019
- Alkem crossed the revenue milestone of USD 1 billion.
- Alkem received the Express Pharma Excellence Award at Pharma CXO Summit 2019.
- Alkem Laboratories took over an undertaking from Cachet Pharmaceuticals.
2020
- Alkem launched Favipiravir in India under the brand name 'Alfluenza'.
- Alkem received the 'Best IT team of the Year' award at the CIO Conclave and Awards 2020.
2021
- Alkem launched Ibuprofen and Famotidine Tablets in the United States.
- Alkem launched Perampanel Tablets in India under the brand name 'Perampil'.
- Alkem launched Brivaracetam in India under the brand name 'Brivasure'.
- Alkem partnered with Tata Memorial Hospital.
- Alkem was recognized as one of India's Best Workplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year.
2022
- Alkem signed a license agreement with Harvard University's Office of Technology Development.
2023
- The Company entered into a co-development and license agreement with Biosergen AB for the development and commercialization of BSG005.
- The NCLT approved the Scheme of Amalgamation for the merger of Pharmasofttech Awacs Pvt. Ltd. into Pharmarack Technologies Pvt. Ltd.
Open Your Free Demat Account Now!
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800